{"id":"duovent-hfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL232642","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction, while albuterol stimulates beta-2 adrenergic receptors to promote bronchial smooth muscle relaxation. The combination provides complementary bronchodilation through two distinct mechanisms, offering improved airflow compared to either agent alone.","oneSentence":"Duovent HFA is a combination inhaler containing ipratropium bromide (anticholinergic) and albuterol/salbutamol (beta-2 agonist) that works synergistically to relax airway smooth muscle and improve bronchodilation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:42.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Acute bronchospasm relief in COPD patients"}]},"trialDetails":[{"nctId":"NCT03910985","phase":"PHASE4","title":"Assessment of Reactance Parameters Measured by the Forced Oscillation Technique for the Bronchodilator Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire UCLouvain Namur","startDate":"2019-04-23","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DEATH"},{"count":2,"reaction":"DRUG INTERACTION"},{"count":2,"reaction":"DYSURIA"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"METASTASES TO BONE"},{"count":2,"reaction":"PRIAPISM"},{"count":2,"reaction":"PRURITUS"},{"count":1,"reaction":"ADRENAL GLAND CANCER"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"APPARENT DEATH"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Duovent HFA","genericName":"Duovent HFA","companyName":"Centre Hospitalier Universitaire UCLouvain Namur","companyId":"centre-hospitalier-universitaire-uclouvain-namur","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duovent HFA is a combination inhaler containing ipratropium bromide (anticholinergic) and albuterol/salbutamol (beta-2 agonist) that works synergistically to relax airway smooth muscle and improve bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Acute bronchospasm relief in COPD patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}